S ince its initial cloning in 1992, SCN5A (Nav1.5) has become known as "the" cardiac sodium channel. 1 SCN5A encodes a tetrodotoxin (TTX)-resistant channel that is responsible for the inward sodium current (I Na ), which initiates the cardiac action potential. Its RNA and protein expression dominate the sodium channel landscape in the ventricle, atrium, and specialized conduction system. Mice heterozygous for a targeted Scn5a deletion (Scn5a ϩ/Ϫ mice) have slowed conduction along with atrial and ventricular arrhythmias, whereas homozygous targeted deletion in mice is embryonic lethal. 2 In humans, pharmacological agents that block SCN5A such as flecainide, developed as antiarrhythmics, are proarrhythmic and increase mortality in patients with structural heart disease. 3 In addition, SCN5A mutations cause a potpourri of diseases that lead to sudden cardiac death including long-QT syndrome type 3 (LQT3, gain-of-function mutations that slow inactivation and increase late sodium current, I Na,L ), Brugada syndrome (BRS1, loss of function mutations that decrease peak I Na ), conduction disease, atrial fibrillation, and dilated cardiomyopathy. 4 More recently, changes in SCN5A (expression, splicing, posttranslational modifications including CaMKII phosphorylation) and/or its ␤-subunits that decrease peak I Na or increase I Na,L have been implicated as potential contributing factors for more common types of sudden death from acquired heart diseases such as heart failure. 5-8
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A number of independent lines of evidence have suggested that other sodium channels might play important roles in the heart. In the mouse, Scn5a is preferentially localized at intercalated disks, whereas Nav1.1, Nav1.3, and Nav1.6 are localized in t-tubules. 9 Consistent with this, TTX-sensitive sodium channels were shown to be responsible for 16% of the sodium channel mRNA and 8% of the peak I Na in isolated adult cardiac myocytes and were upregulated in cardiac myocytes isolated from rats with thoracic aortic bandinginduced heart failure and increased I Na,L . 10,11 SCN10A (Nav1.8) is another TTX-resistant sodium channel located adjacent to SCN5A on human chromosome 3p21-22 that was originally identified in neurons. 12, 13 Scn10a mRNA is also expressed in both in isolated mouse atrial and ven-tricular myocytes, and Scn10a Ϫ/Ϫ mice have shorter PR intervals during ambulatory telemetry monitoring than wild-type littermates. In contrast, other investigators have shown that wild-type mice treated acutely with the Scn10aspecific blocker A-803467 have longer PR and wider QRS intervals during both ambulatory telemetry monitoring and invasive electrophysiology studies. 14 Thus, the molecular evidence favors a role for other sodium channels in general and Scn10a in particular in the rodent heart.
SCN10A mRNA is also expressed in human heart tissue. 13 Unexpectedly, evidence for a role for SCN10A in human cardiac electrophysiology came from genome-wide association studies (GWAS). Using PR and/or QRS intervals as intermediate phenotypes suggestive of conduction disease and arrhythmia susceptibility, several independent loci within SCN10A were identified by GWAS and verified in white, Asian, and African American cohorts. [13] [14] [15] [16] Of note, SCN10A variants that prolonged conduction time were also associated with decreased risks of atrial fibrillation in the CHARGE consortium 17 and ventricular fibrillation in the setting of an acute myocardial infarction. 13 Until now, the mechanism(s) and cells responsible for the effects of SCN10A on cardiac electric activity were unclear.
In the current issue of Circulation Research, two potential roles for SCN10A are identified. Yang et al show that heterologous expression of SCN10A in ND7/23 cells gives rise to a robust, relatively slowly activating and inactivating sodium current that activates at more positive potentials and gives rise to a larger late current than SCN5A. 18 They then show that Scn10A expression is greater in the atria and right ventricle compared with the left ventricle, that A-803467 has no effect on peak I Na but blocks a component of I Na,L in mouse ventricular myocytes, that A-803467 shortens action potential duration (APD) at slow stimulation frequencies in some (but not all) mouse and rabbit ventricular myocytes, that myocytes from Scn10a Ϫ/Ϫ mice have less I Na,L at baseline and no A-803467-sensitive current, and that A-803467 suppresses early afterdepolarizations in mouse and rabbit ventricular myocytes treated with the sodium channel opener ATX-II. They conclude that SCN10A expression contributes to I Na,L in cardiac myocytes, directly modulates cardiac electrophysiology, and is a potential target for antiarrhythmic intervention. Verkerk et al, on the other hand, show that an antibody to Scn10a heavily stains mouse dorsal root ganglia, intracardiac ganglia, and freshly isolated choline transferase positive intracardiac neurons while only weakly staining cardiac muscle and not staining isolated ventricular myocytes. 19 They then show that A-803467 partially blocks peak I Na in isolated intracardiac neurons (with a subpopulation of cells that are more sensitive to the blocker), speeds inactivation and causes a left shift of steady-state inactivation in isolated neurons but not ventricular myocytes, slows firing frequency of neurons depolarized by inward current, and has no effect on action potential parameters from isolated atrial or ventricular myocytes stimulated at relatively high rates. They conclude that SCN10A expression regulates the firing patterns of intracardiac neurons, directly or indirectly affecting cardiac conduction, and represents a potential target for future arrhythmia research.
At first glance, the findings of these two original articles may appear inconsistent; they are not. Yang et al (2012) clearly showed the functional presence of Scn10a in a subset of mouse ventricular myocytes. They made no attempt, however, to identify the presence of intracardiac neurons or study their effects; in fact, the preparations that they used for real-time PCR probably contained intracardiac neurons. Verkerk et al (2012) , on the other hand, clearly showed the functional presence of Scn10a in a subset of mouse intracardiac neurons. Their electrophysiological studies on mouse cardiac myocytes were not designed to identify changes in I Na,L or in APD at slow pacing rates. Both groups found very low if any expression of Scn10a in mouse left ventricular myocytes and no change in peak I Na or in APD at fast pacing rates in ventricular myocytes treated with A-803467. There are other interesting parallels between the studies. In both cardiac myocytes and intracardiac neurons, there are populations of cells with very different levels of Scn10a expression, and blockade of Scn10a by A-803467 suppresses excitability.
It is currently unclear whether the expression of SCN10A in cardiac myocytes or intracardiac neurons is responsible for the GWAS phenotypes. One finding from the mouse studies may shed some light on the situation. As noted above, Scn10a Ϫ/Ϫ mice (which have deletion of the channel from both myocytes and cardiac neurons) have short PR intervals, whereas mice treated acutely with an Scn10a blocker (which would block both types of channels as well) have long PR intervals. 13, 14 Although this could be the result of acute versus chronic lack of the channel, another possibility is that the channel is physiologically relevant in both myocytes and neurons, with differential effects depending on the experimental conditions. Additional studies localizing functional expression of the channel to specific cell types within the heart could be useful. Similarly, a cardiac restricted Scn10a Ϫ/Ϫ mouse could help to sort out the components related to neurons versus myocytes.
In general, nonsynonymous coding single nucleotide polymorphisms that change a protein's amino acid sequence are thought to cause most of the phenotypes identified by GWAS. For Scn10a, this may not be the case. Boogaard et al (2012) used chromatin immunoprecipitation (ChIP) and massive parallel sequencing in mice overexpressing the conduction system regulating transcription factors Tbx3, Nkx2-5, and Gata4 to identify an enhancer element in Scn10a. 20 Of note, a single nucleotide polymorphism (rs6801957, GϾA) is present in the enhancer, and the minor allele is markedly less sensitive to stimulation by TBX5 and repression by TBX3. This element could potentially drive the variable expression of Scn10a in murine cardiac myocytes and neurons and explain differences in conduction system properties and arrhythmia susceptibility in humans.
In summary, an unexpected sodium channel was put into the spotlight by GWAS. To define its role in cardiac electrophysiology, Yang et al tested the hypothesis that Scn10a functionally modulates I Na,L and early afterdepolarizations in cardiac myocytes, and Verkerk et al tested the hypothesis that Scn10a functionally modulates the firing frequency and activity of intracardiac neurons. Both hypotheses proved true, leading to a number of questions. Is the regulation of SCN10A expression part of a coordinated system under the control of T-Box transcription factors, and is it linked in some way to the expression of SCN5A? Is one cell type or both responsible for the conduction system phenotype? What about the susceptibility to tachyarrhythmias? Are changes in SCN10A responsible, in part, for increased late sodium current and/or changes in autonomic nervous system activity seen in pathological conditions such heart failure? Could SCN10A, whether in myocytes and/or neurons, be a target for antiarrhythmic agents? These and other questions await future studies that are sure to come. When it comes to regulating cardiac sodium currents, however, SCN5A is no longer the only sheriff in town.
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